Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Eli Lilly and Company descubre, desarrolla, fabrica y comercializa productos farmacéuticos humanos en los Estados Unidos, Europa, China, Japón e internacionalmente. La empresa ofrece productos para la salud cardiometabólica, incluidos Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulina lispro, insulina lispro protamina, insulina lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 para diabetes; Jardiance, Mounjaro y Trulicity para la diabetes tipo 2; y Zepbound para la obesidad.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $86.5B | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B | $24.5B | $22.3B | $21.5B | $20.0B | $21.2B | $20.0B | $19.6B | $23.1B | $22.6B | $24.3B | $23.1B | $21.8B | $20.4B | $18.6B | $15.7B |
| Beneficio bruto | $72.8B | $54.6B | $36.6B | $27.0B | $21.9B | $21.0B | $19.1B | $17.6B | $16.8B | $15.5B | $15.5B | $14.9B | $14.7B | $18.2B | $17.8B | $19.2B | $18.7B | $17.6B | $16.0B | $14.4B | $12.1B |
| % de margen bruto | 84.2% | 83.8% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% | 74.8% | 74.9% | 78.8% | 78.8% | 79.1% | 81.1% | 80.5% | 78.5% | 77.2% | 77.4% |
| Ingresos operativos (EBIT) | $39.7B | $29.7B | $17.5B | $10.8B | $8.7B | $7.9B | $7.2B | $6.0B | $6.0B | $4.2B | $3.9B | $3.6B | $3.3B | $5.5B | $5.0B | $6.3B | $6.8B | $6.4B | $5.5B | $4.8B | $4.1B |
| % de margen operativo | 45.9% | 45.6% | 38.9% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% | 18.0% | 17.0% | 24.0% | 22.2% | 26.0% | 29.3% | 29.2% | 27.1% | 25.8% | 26.3% |
| Ingresos netos | $27.6B | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B | $6.2B | $8.3B | $3.2B | ($204M) | $2.7B | $2.4B | $2.4B | $4.7B | $4.1B | $4.3B | $5.1B | $4.3B | ($2.1B) | $3.0B | $2.7B |
| % de margen neto | 31.9% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% | 12.1% | 12.2% | 20.3% | 18.1% | 17.9% | 22.0% | 19.8% | -10.2% | 15.8% | 17.0% |
| EBITDA | — | $27.9B | $15.2B | $8.6B | $8.7B | $8.0B | $8.9B | $6.9B | $5.5B | $4.1B | $5.1B | $4.4B | $4.5B | $7.5B | $7.0B | $6.9B | $8.0B | $6.9B | $43M | $5.9B | $4.9B |
| Beneficio por acción (EPS) | $30.81 | $22.98 | $11.71 | $5.80 | $6.57 | $5.85 | $6.47 | $8.69 | $3.13 | $-0.19 | $2.49 | $2.18 | $2.15 | $4.19 | $3.57 | $3.90 | $4.58 | $3.94 | $-1.89 | $2.71 | $2.45 |
| Acciones en circulación (M) | — | 898M | 904M | 903M | 950M | 954M | 957M | 958M | 1,034M | 1,052M | 1,101M | 1,105M | 1,111M | 1,117M | 1,146M | 1,114M | 1,106M | 1,098M | 1,094M | 1,091M | 1,087M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de LLY. /companies/us/LLY
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms